Transcript From Clinical Laboratory Diagnostics to reliable Point

a
spin-off
MyLife Technologies
dedicated to microneedle array (MNA) technology
at University of Twente
Flexible designs
Scalable production
“From one needle to multi-needle arrays”
Large choice of properties
“From solid to porous”
Patent pending microneedle array technology, University of Twente/STW
“From few to millions”
High integration capabilities
“From components to systems”
a
spin-off
MNA concept replacing syringes
1. Large-scale MNA fabrication.
1
2. Packaging into point-of-care patch.
3. MNA interface transports molecules pain-less and minimal invasive
through the skin for diagnostics or drug delivery purposes; replacing the
bulky syringe system.
2
1-2 cm
 1mm
Syringe system
3
?
Patent pending microneedle array technology, University of Twente/STW
a
spin-off
Team building & expertise
- Micro- and Nanotechnology
- Microelectronic devices
- Lab-on-a-Chip
- Microfluidics
- Organic chemistry
- Medical coatings
- Optical instrumentation &
measurements
- Academic spin-out
- R&D
Chemical
Technology
Applied
Physics
Applied
Physics
Co-developer
Chemical
Technology
3
a
spin-off
Application fields
• Delivery of active compounds
– Epidermal/intradermal release and targeting
Ø 100 mm
• Biofluid sampling from the skin
– Biomarker and skin property profiling
300 mm
MNA
Ø 2-10 mm
Point-of-care applications &
vaccination programs
MyMNA
Ink-loaded MyLife Technologies’
microneedles
4
a
spin-off
Advantages of microneedle arrays
• Safe, self- limiting insertion
• Broadening the range of compounds
exchanged via the skin
Large molecules, e.g. biomarkers, DNA
Injection into skin, courtesy
Prof. dr. J.A. Bouwstra, LU,LACDR
• Increased efficiency and efficacy
Addressing Langerhans cells
• High integration capabilities
Arrays for Lab-on-a-Chip, controlled release,
user feedback
• Non/minimal-invasive
Microneedles are not perceived as “needles” and are
experienced as a painless device
MyPatch  product impression
5
a
spin-off
Unique selling points
of MyMNA
• Customer specific solutions
– Ceramic or polymer
– Flexible in design and layout
• Advanced functionalities by
– Tailorable porosity
Scanning electron micrograph of a single
needle tip
A
– Increased surface area
– Material’s intrinsic bio-activity
• Scalability of production
• Patent pending
A
A-A
Array cross-section showing absorption
of 45 kDa fluorescent ovalbumin
6
Today 2-3 years
Application specific product development
Application specific product development
Application specific product development
Search for technology co-developer
IP pending technology principle
a
3-15 years
spin-off
Markets and market entry
Specialized Skin Care &
Medical Aesthetics
Sampling of biomarkers &
skin property profiling
Medical therapy &
vaccination
a
spin-off
• Application-specific
co-development
Investment in k€
Intellectual asset transfer
1 - seed
2 - investing
3 - capitalising
New IA
IA
50
5
10
Time in yrs
“MyLife Technologies’ Intelligent skin patch”Your new application!
R. Luttge et al. mTAS 2003
88
a
spin-off
Realisation & business model
For more information please see:
www.mylifetechnologies.nl
or contact us directly:
- [email protected]
- [email protected],
tel. +31 53 489 2742
9
a
Thank you for your interest
spin-off